RE:Another flash crash IBRX (1.3B$US) has 30x our market valuation.
They way more trials ongoing but they were valued a bit higher and they are still awaiting their first FDA approval for our current population (BCG-unresponsive). But as a combo and BCG dependent. They already had a big pharma agreement ongoing (most probably MERCK because of their dependence with BCG).